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Abstract: Controlled drug delivery technology of proteins/peptides from biodegradable 
nanoparticles has emerged as one of the eminent areas to overcome formulation associated 
problems of the macromolecules. The purpose of the present investigation was to develop 
protein-loaded nanoparticles using biodegradable polymer poly L-lactide-co-glycolidic acid 
(PLGA) with bovine serum albumin (BSA) as a model protein. Despite many studies available 
with PLGA-based protein-loaded nanoparticles, production know-how, process parameters, 
protein loading, duration of protein release, narrowing polydispersity of particles have not been 
investigated enough to scale up manufacturing of protein-loaded nanoparticles in formulations. 
Different process parameters such as protein/polymer ratio, homogenizing speed during emul-
siﬁ  cations, particle surface morphology and surface charges, particle size analysis and in-vitro 
protein release were investigated. The in-vitro protein release study suggests that release proﬁ  le 
of BSA from nanoparticles could be modulated by changing protein-polymer ratios and/or by 
varying homogenizing speed during multiple-emulsion preparation technique. The formulation 
prepared with protein-polymer ratio of 1:60 at 17,500 rpm gave maximum protein-loading, 
minimum polydispersion with maximally sustained protein release pattern, among the prepared 
formulations. Decreased (10,000 rpm) or enhanced (24,000 rpm) homogenizing speeds resulted 
in increased polydispersion with larger particles having no better protein-loading and -release 
proﬁ  les in the present study.
Keywords: bovine serum albumin (BSA), poly-L-lactide-co-glycolidic acid (PLGA), 
nanoparticles
Introduction
Increasing numbers of therapeutic agents emerging from rapid growth of 
biotechnological research components of pharmaceutical drug discovery are 
macromolecules such as proteins (Hermes and Narayani 2002; Muller and Keck 
2004; Kavimandan et al 2006). The advances in recombinant DNA technology 
have ensured the easy and abundant availability of several genetically engineered 
regulatory and therapeutic proteins such as hormones, growth factors, vaccines, 
immunosuppressors and so on. However, various difﬁ  culties are encountered in 
formulating proteins/peptides for therapeutic uses (Hermes and Narayani 2002; 
Wei-Chiang 2003). Proteins cannot be readily delivered orally or through skin due 
to rapid degradation by proteolytic enzymes in the gastrointestinal tract and poor 
pass through the biological barrier, respectively. Due to short biological half-lives, 
repeated injections are generally needed and it is painful. Another serious problem 
in delivering proteins is their inherent physical and chemical instability. However, a 
possible solution to improve biological half-lives is the controlled delivery of proteins 
from biocompatible polymers. While various routes such as ocular, transdermal, International Journal of Nanomedicine 2008:3(4) 488
Mukherjee et al
nasal and buccal have been tried (Banga and Chien 1988; 
Shoyele and Slowey 2006), none of these routes has proved 
to be a potential alternative to the invasive injection. New 
and/or improved methods of administration are being 
constantly tried. Nanoparticles are the nanosize particulate 
dosage forms that are being extensively tried to deliver 
proteins as they can protect the protein from metabolizing 
enzymes and can sustain the release and target speciﬁ  c 
tissues by incorporating surface ligand moieties (Muller and 
Keck 2004). PLGA is a well-characterized biodegradable 
polymer approved for human use by US Food and Drug 
Administration (US FDA) (Chun and Phuong-Truc 2008). 
PLGA has different varieties with different characteristics. 
Many studies (Lamprecht et al 1999; Qaddoumi et al 2004; 
Bilati et al 2005; Lee et al 2007) are available on PLGA 
(50:50)-based nanoparticles, however, few studies (Zhu 
and Schwendeman 1999) have been reported with PLGA 
(85:15), the variety chosen in the present study. PLGA 
(85:15) has a molar ratio of L-lactide and glycolide, 85/15. 
Advantage of the lactide and glycolide copolymers is the 
well documented versatility in polymer properties and 
performance characteristics (Chohen et al 1991; Berkland 
et al 2001). Bovine serum albumin (BSA) was used as model 
protein since it is one of the most stable and widely-used 
proteins for evaluating novel sustained release drug delivery 
system (Ravi Kumar 2000). Great amount of research in the 
ﬁ  eld of biodegradable microparticles and some research 
related to biodegradable nanoparticles, containing peptide 
or protein drugs have been available in the literatures 
(Panyam and Labhasetwar 2003; Mohanraj and Chen Y 
2006). However, production know-how, effects of critical 
parameters inﬂ  uencing successful protein-loading, desired 
protein release pattern, prolonging duration of release, sta-
bility of proteins in formulation, narrowing polydispersity 
of nanoparticles etc. have not been investigated enough to 
formulate them commercially. Rather many more studies 
are required to scale up them as formulations for industrial 
production. Under these circumstances, if we can add even a 
little ﬁ  nding to the existing scientiﬁ  c information, this could 
be valuable in real term in the development of nanoparticles, 
in particular and nanoscience as a whole.
The purpose of the present investigation was to develop 
protein (BSA)-loaded nanoparticles with biodegradable 
polymer, poly L-lactide-co-glycolidic acid (PLGA), using mul-
tiple emulsiﬁ  cation (water-in-oil-in-water, w/o/w) and solvent 
evaporation technique and standardization of various process 
parameters such as protein/polymer ratio, homogenizing speed 
during emulsiﬁ  cations, particle surface morphology and surface 
charges, particle size analysis and in-vitro protein release to 
obtain nanoparticles with maximum protein-loading, minimum 
polydispersion with a maximally sustained protein release 
pattern, among the prepared formulations.
Experiment
Materials
Bovine serum albumin (BSA) and poly L-lactide-co-glycolidic 
acid (85:15), PLGA, were procured from Sigma-Aldrich 
Chemicals Pvt. Ltd., Bangalore, Karnataka, India. 
Polyvinyl alcohol (PVA, M.W. 30,000–70,000) was obtained 
from S.d Fine Chem. Ltd., Mumbai, Maharastra, India. 
Dichloromethane (DCM) was purchased from E.Merck Ltd., 
Mumbai, Maharastra, India. All other chemicals used were 
of analytical grade.
Methods
Method of preparation of nanoparticles
Required amount of PLGA (Table 1) was taken in a beaker and 
dissolved in DCM. Then a speciﬁ  ed amount of it was added to 
2.5% of  PVA containing BSA and was homogenized for 4 min 
at speciﬁ  ed rpm. The above mixture was added dropwise to 
75 mL of 1.5% PVA in a 400 mL capacity glass beaker and 
homogenized for 6 min at speciﬁ  ed rpm (Table 1) to produce 
w/o/w emulsion. The emulsion was then stirred on a magnetic 
stirrer overnight to evaporate DCM. The nanoparticles were 
then washed thrice using double distilled water by centrifuga-
tion at 16,000 rpm for 40 min. Samples were frozen for 3 h 
at −20 °C and freeze-dried for 48 h in 10 mL freeze drying 
vial (initial self-temperature was −15 °C and it was reduced 
to −40 °C and kept for 48 hours). Self-temperature was then 
elevated to 15 °C and removed.
Characterization of protein-loaded 
nanoparticles
Study of protein excipients interaction through 
fourier transform infra-red spectroscopy
The pure protein, mixture of protein with PLGA and PVA 
and mixture of PLGA and PVA were mixed separately 
Table 1 Batch speciﬁ  cation
Formulation 
code
BSA: PLGA 
ratio
Speed of homogenization 
(rpm)
G1 1:50 10,000
G2 1:50 12,500
G3 1:50 15,000
G4 1:60 17,500International Journal of Nanomedicine 2008:3(4) 489
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with IR grade KBr in the ratio 1:100 and corresponding 
pellets were prepared by applying 5.5 metric ton of pressure 
in a hydraulic press. The pellets were scanned over a wave 
number range of 4000 to 400 cm−1 in Magna IR 750 Series II 
(Nicolet, Madison, WI, USA) fourier transform infra-red 
(FTIR) instrument.
Determination of polydispersibility
Polydispersibility was performed by the instrument Zetasizer 
nano ZS with DTS software (Malvern Instrument Limited, 
UK). NIBS® (noninvasive backscatter optics) technology 
was used for measurements of particles. The formulations 
were taken in lyophilized form in microcentrifuge tubes, 
suspended in phosphate buffer, pH 7.4 and introduced in the 
instrument to read the results.
Determination of zeta potential
Zeta potential of different formulations was measured by the 
instrument zetasizer nano ZS using DTS software (Malvern 
Instrument Limited, UK) using M3-PALS technology. 
The experimental formulations were taken in lyophilized 
form in 2 mL eppendrof tube and the samples were suspended 
in phosphate buffer, pH 7.4 and then introduced in the 
instrument following the guideline of the manufacturer. 
The results were then read.
Study of morphology of nanoparticles by scanning 
electron microscopy
Surface morphology was determined by scanning electron 
microscopy (JEOL, JSM5200, TOKYO, Japan). The samples 
were spread on metal stubs and gold coating was done by 
using an ion-sputtering device. The gold-coated samples 
were vacuum dried and then examined.
Protein-loading study
A known amount of protein-loaded nanoparticles were 
added to a solution of 5% SLS-NaOH. After a deﬁ  nite 
period of time, the dispersed phase was separated from 
the continuous phase by means of centrifugation. Then 
the supernatant was collected and released protein was 
assayed spectrophotometrically using Bio-Rad Protein 
Assay Kit.
Release study
Protein-loaded formulations (5 mg) were weighed and 
suspended in 1mL phosphate buffered saline in 2 mL 
eppendrof tubes. They were then incubated at 37 °C  with 
constant shaking. The samples were kept for speciﬁ  ed periods 
of time (2, 5, 10, 15, 20, and up to 50 days, respectively) and 
were analyzed for protein determination.
Results
Drug-excipient interaction study is an important study 
to formulate a chemical entity with the other chemicals 
in a sustained release delivery system, so that the desire 
release pattern and other requisite physico-chemical 
characteristics may be achieved (Mukherjee et al 2005a). 
Among the various methods available, FTIR spectroscopy 
provides us a distinct idea regarding interaction between 
various functional groups present in drug and excipients 
(Cunha-Filho et al 2007). In the present study when the FTIR 
spectrum of BSA, PLGA-PVA and BSA with PLGA-PVA 
(Figures 1, 2, and 3) were compared, no physico-chemical 
interaction was detected. Hence, the polymer was used to 
formulate the protein.
The results of particle size analysis by laser diffraction 
showed that particle sizes varied from 50 nm to 985 nm 
with variable polydispersity indices among the experimental 
formulations (Table 2). About more than 70% particles found 
to have diameter below 700 nm. However, the densest and 
narrowest range of particle dispersion was noticed between 
300 nm and 600 nm in case of formulation G4 (Figure 4), 
among the prepared formulations.
Table 2 depicts the various process parameters of 
the prepared protein containing nanoparticles. Formu-
lation G4 had the least value of the average diameter, 
whereas G1 had the maximum. The polydispersibility indices 
also showed the similar patterns of dispersibilities ie, for-
mulation G4 had the least value and G1 had the maximum. 
All the formulations had negative zeta potential values varied 
between −3.85 to −4.81 mV. G4 had the value of −4.30 mV 
whereas G1 had −3.85 mV. When mobility was compared 
G4 had a lower mobility value of –0.2260 as compared to 
that of G1, which was –0.3022. Conductivity was found to be 
the highest (21.23 ms/cm) in G4 among all the experimental 
formulations and the least value was seen in G1, which was 
10.37 ms/cm.
SEM photograph (Figure 5) shows that the prepared 
particles were spherical in shape and a major portion of the 
particle distribution was occupied by very small particles in 
nano range size as compared to the larger particles which 
were also below 1 μm in size. This was further conﬁ  rmed 
by particle size analysis, which showed that size distribu-
tion varied from 50 nm to 985 nm range. There was a 
clear distribution of both the small and large particles and 
they were not conglomerated. Again the denser particle International Journal of Nanomedicine 2008:3(4) 490
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Figure 1 FTIR spectra of BSA.
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distribution was seen between 300 nm and 600 nm, with an 
average particle size 497 nm.
The average (n = 6) protein loading in G4 formulations 
was found to be 38.6% w/w of the formulations.
Protein release study was carried out to understand the 
protein release pattern from the formulations. After 10 days 
release of the protein was about 30% of the protein content.
When protein release study was conducted it was found 
that the cumulative amount of the protein release in 50 days 
was 83.52 μg per mg of formulation in case of G1. The 
values were 82.31, 72.35, 60.75 μg per mg of formulation 
in case of G2, G3 and G4, respectively (Figure 6). When 
the cumulative percentages of the protein release from the 
experimental formulations were plotted against time, it was 
found that about 84% protein was released in 50 days in 
case of the formulation G3, whereas, G4 had a release of 
about 42% in the same time period (Figure 7). G1 and G2 
had a cumulative percentage release of about 61% and 77%, 
respectively.
From the release kinetics it was evident that formulation 
G1, G2 and G3 followed zero order kinetics, whereas, G4 was 
closest to apparent zero order kinetic (Table 3).
Discussion
In the present study, PLGA was selected to formu-
late BSA-loaded nanoparticles. Initially drug-excipient 
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Figure 3 FTIR spectra of BSA and excipients.
Table 2 Characterization of protein-loaded nanoparticles
Formulation 
code
aZ-Ave (nm) Polydispersibility Zeta potential 
(mV)
Mobility Conductivity 
(ms/cm)
Loading capacity 
(%) ± SD (n = 6)
G1 918 0.050 −3.855 −0.3022 10.37 25.19 ± 0.085
G2 795 0.032 −4.674 −0.3664 11.53 28.17 ± 0.014
G3 612 0.016 −4.816 −0.3776 18.98 31.19 ± 0.083
G4 497 0.013 −4.300 −0.2260 21.23 38.29 ± 0.085
Note: aZ-Ave represents average particle size diameter.International Journal of Nanomedicine 2008:3(4) 492
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interaction study was conducted since it is an important study 
to determine if there is any interaction between the drug and 
the excipients (Ya-Ping 2001). Drug-excipient interaction 
predicts the characteristics of drug release from a formulation 
(Mukherjee et al 2005b). The level of interaction between 
BSA and PLGA at the level of functional groups through 
FTIR spectroscopy has not been reported so far in the litera-
ture. In the present experiment, the BSA-excipient interaction 
study was conducted with the help of FTIR spectroscopy, 
which is one of the latest and very powerful techniques that 
can indicate drug-excipient interactions among the various 
functional groups between the drug (protein) and the excipi-
ent molecules (Maghraby and Ali 2007). Our data reveal 
that no predominant interaction existed between the protein 
and the excipients. Hence, PLGA and PVA were selected 
to formulate BSA.
Polydispersity varies from formulations to formula-
tions. Reports have shown that the polydispersity variation 
existed from 100 nm to even 20 μm (Panyam et al 2003; 
Qaddoumi et al 2004; Han et al 2005). Variation in a range 
of few hundred nm is also very common (Song et al 1997). 
However, the denser mode of particle sizes in polydisper-
sity range is important to compare polydispersity data with 
the other ﬁ  ndings and in our study this has existed between 
300 nm and 600 nm with about 70% particles below 700 nm 
size. Thus the ﬁ  nding is very encouraging in terms of less 
polydispersity of particle size in real terms.
Zeta potentials reported for PLGA based nanopar-
ticles were found to vary from −3.54 mV to −4.04 mV 
(G´omez-Gaete et al 2007). The ﬁ  ndings of zeta potential 
study are given in Table 2. In the present study this value is 
within the range. Particles with zeta potentials more positive 
than +30 mV and more negative than −30 mV are normally 
considered stable for colloidal dispersion (Yue et al 2008). 
From the data it is evident that all the formulations are 
unstable in the colloidal state. This suggests that the particles 
should not be stored in a liquid suspension form and rather 
they should be stored in a lyophilized state. Immediately 
before the administration they should be reconstituted. 
Reports suggest that formulations stored in colloidal stage 
cause more stability problem than in the dry form (Abdel-
wahed et al 2006).
Poly (ethylene glycol)-poly (L-histidine)-diblock 
copolymer is an effective excipient preserving stability of 
BSA-PLGA microspheres in aqueous solution (Kim et al 
2005). PLGA degrades through acid catalyzed hydrolysis 
and produces carboxylic acids. Neutralizing the acidic 
microenvironment with the degraded PLGA microsphere 
system caused an improved release kinetics and stability 
of the encapsulated protein. Poly(ethylene glycol)-
poly(L-histidine)-diblock copolymer forms an ionic complex 
with a negatively charged BSA with a pH range 4.9–6.5 and 
being a weekly basic component it can neutralize acidic 
microenvironment of PLGA created by acid degradation 
Nanometer ranges
40
35
30
25
20
15
10
5
0
50 300 500 600 700 800 900 1000
P
e
r
c
e
n
t
a
g
e
s
 
o
f
 
n
a
n
o
p
a
r
t
i
c
l
e
s
Figure 4 Polydispersity pattern of G4.International Journal of Nanomedicine 2008:3(4) 493
Sustained release protein-loaded nanoparticles
product. PLGA coated with poloxamer (Pluronic F68) is 
also reported (Santander-Ortega et al 2006) for improved 
stability in colloidal state.
The SEM study (Figure 5) shows smooth and spherical 
shaped spheres in nano range. The average particle sizes of 
the formulations prepared at 10,000, 12,500, 15,000, and 
17,500 rpm are reported in Table 2. The data suggest that 
with increasing homogenizing speed average diameters of 
particles were reduced. However, when speed of homogeni-
zation was further enhanced, it was found interestingly that 
the average diameters of the particles were increased again. 
At 24,000 rpm, the average diameter became in micron range 
(approximately 2.869 μm). Higher energy due to higher 
homogenizing speed might have agglomerated nanospheres 
immediately after formation to provide larger spherical 
structures due to variable surface charges or any other similar 
cohesive forces generated due to the high energy process.
Protein loading is found to vary due to formulation 
compositions, methodology, process parameters etc. 
PLGA (50:50) was reported to have protein loading of 
8–16% (Lgartua et al 1998), which is about 2–4 times more 
ie, ∼38% in the experimental formulations prepared with 
PLGA (85:15), in the present study. Improved BSA loading 
was achieved in the prepared formulation G4 (38.6%) in the 
present study. The protein-loading studies show that with 
increase in speed of homogenization, the loading capacity 
of formulation was increased. Likewise, the increase in 
amount of polymer also enhanced the loading of protein. 
High homogenizing speed might vary the surface charges, 
which ultimately could load more protein (Basarkar et al 
2007). The in-vitro protein release study was carried out 
for a period of 50 days. We studied a pretty long period 
for studying sustained release of protein. However, litera-
ture showed variable protein release study period from 35 
days to 70 days (Zhu and Schwendeman 1999; Leach et al 
2005).
Poly (lactide-co-glycolide) (PLGA), aliphatic polyester, 
has been well documented for its excellent biodegradability, 
biocompatibility and nontoxic properties (Loo et al 2004). 
PLGA varieties differ in their lactide-glycolide ratios which 
make PLGA varieties available in different molecular 
weights with variable physicochemical properties. 
The mechanical strength, swelling behavior, capacity to 
undergo hydrolysis, and subsequently the biodegradation 
rate are directly inﬂ  uenced with the lactide content of the 
PLGA polymer (Jain 2000). Present study was conducted 
with a more uncommon PLGA (85:15) than the commonly 
used PLGA (50:50) variety. Lactic acid is more hydrophobic 
than glycolic acid and hence lactide-rich PLGA (85:15) 
is less hydrophilic, absorbs less water, and subsequently 
degrade more slowly than PLGA (50:50) (Jain 2000). 
PLGA polymer containing lactic and glycolic acids in 85:15 
ratio is hydrolyzed much slower than the PLGA (50:50) 
containing equal proportion of lacdide and glycolide. 
Molecular weight is indicative of chain length of polymers. 
By varying PLGA molecular weight, degradation of the 
Figure 5 SEM photograph of the formulation G4.International Journal of Nanomedicine 2008:3(4) 494
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Figure 6 Cumulative amount of BSA released from the experimental formulations. Data shows mean ± SD (n = 6).
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Table 3 Release kinetics of BSA
Formulation code Zero order First order Higuchi kinetics
G1 y = 0.816x + 20.791
aR  2 = 0.9902
y = −0.0063x + 1.9152
R  2 = 0.9801
y = 7.0522x + 8.2225
R  2 = 0.9597
G2 y = 0.952x + 29.41
R  2 = 0.9967
y = −0.0096x + 1.8855
R  2 = 0.9705
y = 8.2168x + 14.798
R  2 = 0.9635
G3 y = 0.8795x + 40.416
R  2 = 0.9898
y = −0.0111x + 1.8204
R  2 = 0.9714
y = 7.6683x + 26.553
R  2 = 0.9764
G4 y = 0.2429x + 29.625
R  2 = 0.923
y = −0.0016x + 1.8485
R  2 = 0.9312
y = 2.1136x + 25.817
R  2 = 0.9066
Note: aR represents regression coefﬁ  cient.
polymer and the release kinetics of BSA can be controlled. 
Higher molecular weight of PLGA (85:15) than PLGA 
(50:50) due to the presence of higher lactide chain lengths 
enhances the hydrophobicity and decreases the degradation 
of the polymers and rate of protein release. In the present 
study, the nanoparticles containing larger particles with the 
increased polydispersity indices showed slower release of 
BSA and it might be due to longer diffusion pathways of 
BSA in larger particles. However, more content of PLGA 
(85:15) showed the slowest BSA release in G4 among the 
formulations studied and it might be due to the enhancement 
of hydrophobicity. In the present study, the protein loading 
shows that increase in speed of homogenization increased 
the loading capacity of the formulation. Likewise, the 
increase in amount of polymer also enhanced the loading 
of protein. Increased entrapment efﬁ  ciency was observed 
for particles of PLGA (85:15) with than PLGA (50:50), for 
their higher molecular weight and stronger hydrophobicity 
(Mittal et al 2007). Higher homogenizing speed might 
vary the surface charges of the polymers (Basarkar et al 
2007), which ultimately could load more protein. In a study 
nanoparticles based on PLGA (85:15) without drug was 
showed to produce less polydispersity index than those 
with PLGA (50:50) (Mittal et al 2007). About 5% statisti-
cally nonsigniﬁ  cant enhancement of nanoparticle sizes 
with PLGA (85:15) than PLGA (50:50) was reported in the 
literature (Mittal et al 2007). This indicates that increase 
lactide chain may not have great inﬂ  uence on particle 
size; rather the methodology has direct impact on the size 
reduction. In our study, variable homogenizing speed was 
found to be responsible for the size of nanoparticles and 
their polydispersity index.
Figure 6 and Figure 7 summarize the ﬁ  ndings of in-vitro 
protein release study. Particles with smaller average diam-
eter showed slower release. Smaller particles are generally 
formed with higher impact (Chen et al 2007). It varies the 
tortuous polymeric diffusion pathways in smaller particles 
(Zhang et al 2004). This ultimately leads to a sustained dif-
fusion of protein from the particles. Formulations prepared 
with a BSA: PLGA ratio of 1:60 showed the slowest release 
pattern, among the formulations studied. Thus incorporation 
of extra amount of hydrophobic polymer, PLGA, might have 
caused more tortuous polymeric networks to deliver the 
protein for prolonged period of time maximally, among the 
experimental formulations.
The method provided a narrow-ranged densely-dispersed 
nanoparticles having capability of release of protein (BSA) 
more than 50 days. Thus, by regulating different process 
parameters and using a very simple method, BSA-loaded 
nanoparticles with a low polydispersity index can be 
produced and improved BSA loading and prolonged release 
proﬁ  les of BSA can be achieved.
Conclusion
PLGA polymer can be used to prepare nanoparticles containing 
BSA or similar proteins. Narrow-ranged densely-dispersed 
nanoparticles having a good protein- loading capacity and slow 
and sustained protein release characteristics could be devel-
oped using this simple technology. From the data provided, 
it is evident that nanoparticles prepared at 17,500 rpm with a 
protein: polymer ratio of 1:60 satisﬁ  ed the above criteria better 
than the other experimental formulations and hence it may be 
considered as the best among the prepared formulations, for 
further investigation.
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